Skip to content

Deferred Revenue at other companies

AptarGroup logo
AptarGroupATR
$79.8M-0.3%
Dow logo
DowDOW
$197M+0.5%
Trimas logo
TrimasTRS
$10.58M+43.8%
UFP Technologies logo
UFP TechnologiesUFPT
$4.63M-3.5%
Lifecore Biomedical, Inc. logo
Lifecore Biomedical, Inc.LFCR
$5.86M
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO

Other financials

Income statement

See full
Revenue$872.3M+13.8%
Gross profit$329.2M+20.2%
Operating income$179.1M+16.5%
Net income$154.0M+16.8%
EPS (diluted)$2.15+18.1%

Balance sheet

See full
Cash & equivalents$435.8M-14.5%
Total debt$316.5M+2.7%
Total equity$3.0B+2.1%
Total assets$4.1B+3.1%

Cash flow

See full
Operating cash flow$124.0M-30.0%
CapEx$43.2M-42.6%
Free cash flow$80.8M-20.7%

Valuation

See full
Market cap$23.75B+32.5%
Enterprise value$23.63B+33.4%
P/E42×+5.3×
P/S7.1×+1.1×

Profitability

See full
Gross margin36.8%+1.5pp
Operating margin20.5%+0.8pp
Net margin17%+0.5pp
FCF margin13.1%+1.5pp

Returns & leverage

See full
Return on equity19.1%+1.4pp
Debt / equity0.1×0.0×
Current ratio2.8×0.0×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: West Pharmaceutical Services’s 10-Q, filed July 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about West Pharmaceutical Services's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is West Pharmaceutical Services's deferred revenue?
West Pharmaceutical Services (WST) reported deferred revenue of $3.6M in Q2 2026.
How has West Pharmaceutical Services's deferred revenue changed year-over-year?
West Pharmaceutical Services's deferred revenue increased by 28.6% year-over-year, from $2.8M to $3.6M.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.